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Relapse in schizophrenia: Current issues
• Nature of relapse
• What causes Relapse
• How to minimize
• What is beyond relapse prevention in 
improving outcome
Relapse: ‘Life is never the same again’
• Expected in 70% patients after First episode
• 70% of patients show an incomplete remission 
after first episode
• This includes Cognitive decline ( in 55%)
• persistence of negative symptoms ( in 41%), 
• often associated with Social disabilities, 
• Social Decline and a worsened QOL.
• Risk of relapse after an episode remained 
increased throughout the  life.
Outcome-Recent Studies, Early Intervention
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Cumulative Recovery Rate in First episode 
schizophrenia: Robinsons et  al, JCP 2006
Schizophrenia Relapse rates
Survival Analysis of optimal NL dose and 
real world  rehospitalization risk for 
multiepisodic NL responsive schizophrenia
Cost of Relapse in Schizophrenia 
By Peter J. Weiden and Mark Oltson
Schizophrenia Bulletin, Vol. 21, No. 3, 1995
Relapse : when and how it Occurs
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Relapse is 
one of the 
outcome 
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Underlying 
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irrespective and 
independent of 
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onset, treatment 
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What relapses: 
positive 
symptoms, depressi
on and suicide, lack 
of self 
care, competency
Not relapsed does not mean 
good functioning. Non-
relapsing patients do have 
disability, dysfunction and 
poor QOL.
Relapse
The patient The illness The treatment
The environment 
and familyAll  of these  components
Determinants of Relapse
Risk factors
Possible
Mechanisms
Time to Remission
Protective Factors: 
personal resource,  good premorbid adjustment, a 
positive self concept & a competent social network
Dixon LB, Lehman AF (1996), Schizophrenia Bullatin, 21(2): 631-643
DixonLBet al (1995) Schizophrenia Bullatin, 21(4): 567-577, 
World Health Report,WHO,2001
Effectiveness of intervention for Schizophrenia: 
Relapse rate
First-episode schizophrenia versus chronic schizophrenia 
treated with risperidone (2)
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Efficacy and effectiveness of Antipsychotic 
Medications: Annual Relapse Rate
Effectiveness of Antipsychotic Dugs in Schizophrenia
(Lieberman et al , 2005)
Cognitive behavior Therapy for residual symptoms in 
Schizophrenia Patients in Community 
( Dickerson & Lehman,  2005) 
Combining Medication and Family 
Education in Schizophrenia; Relapse Rates
Relapse rate in 2 years 
with Oral Vs LA Depot APD combined with 
psychosocial intervention, Schoolar et al , 2006
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Are Antipsychotics superior to psycho-
social & cognitive behavioural therapies 
in relapse prevention of schizophrenia? 
• Evidence is equivocal 
Thus ,there is a clear case for integrated and 
comprehensive therapy right from the day of 
the first contact; irrespective of the clinical 
settings; situations and alliances .
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Agid et al. Neuropsychopharmacology.2007.
Antipsychotic Response is a function of 
5HT2a & D2 blocking Ratio


Genetics - Examples
• An example of how a genetic 
predisposition for 
schizophrenia can be triggered 
by environmental influences 
can be seen in a research 
study taken from Biological 
Psychiatry, Volume 57:
– Indicates that people who had 
multiple copies of a version of 
the COMT gene and who 
smoked marijuana had a 1,000% 
increase in their risk of 
developing schizophrenia
• Another example from the 
British Journal of Psychiatry:
– Indicates that adopted 
children with high 
genetic/biological risk for 
schizophrenia (their mother 
had schizophrenia) had an 
86% lower rate of developing 
schizophrenia raised in a 
healthy vs. a dysfunctional 
family. 
– Only 6% of the children 
developed schizophrenia in 
the healthy family. 
– 37% of the children of the 
dysfunctional families 
developed schizophrenia
(as cited on  www.schizophrenia.com).
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Why does comorbidity develop??
Why is Medication Not Sufficient?
• Neurodevelopmental dyfunction
• Subtle neurocognitive deficits from early
childhood 
• Diffuse system disruption
• Timing of first exacerbation disrupts adult
socialization
• Residual primary and secondary negative
symptoms
Impact of Non-Adherence
1. Malla et al. Psychol Med 2006;36:649-58
2. Robinson et al. Arch Gen Psychiatry 1999;56:241-7
Non-adherence Associated with Poorer 
Functional Outcomes (n=1906)4
3. Ward et al. Clin Ther 2006;28:1912-21
4. Ascher-Svanum et al. J Clin Psychiatry 2006;67:453-60
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Expressed emotion and psychiatric 
relapse: a meta-analysis.
Community-Based Treatment of Schizophrenia and Other Severe Mental 
Disorders: Treatment Outcomes
cumulative relapse/rehospitalization rates during 18 to 24 months in randomized controlled 
trials of long-term family intervention for schizophrenia.
Kim T. Mueser, PhD, Gary R. 
Bond, PhD, Robert E. Drake, MD, PhD
Medscape General Medicine 3(1), 2001
Specialized programs for relapse prevention are more effective in 
identifying prodomal episodes before  frank relapse
‘A Program for Relapse Prevention in Schizophrenia: A Controlled Study’
Marvin I. Herz, et al
Arch Gen Psychiatry. 2000;57:277-283. 
Nature of Illness as Determinants of 
Relapse
• low serotonergic and high dopaminergic 
neurotransmission are associated with a relapse,
• possibly high noradrenergic neurotransmission plays 
a role in short-term relapses.
• Role of Certain cytokines, which have rarely been 
studied to date, seem to have an even higher impact 
on schizophrenic relapse. 
Biological mechanisms of relapse may not become fully 
elucidated before the mechanisms of the schizophrenic 
pathophysiology are clarified.
Week following haloperidol withdrawal model, likelihood ratio   p < 0.0005
Plasma HVA
Biological studies and Relapse
Week following haloperidol withdrawal model, likelihood ratio p < 0.0005
Plasma MHPG
Biological studies and Relapse
Relevance of Neuro-cognitive deficits for 
functional outcome in schizophrenia
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Can Neurocognitive Functioning Be 
Improved with Psychosocial 
Interventions?
Strategies for reducing 
Cognitive Demands
Stress-diathesis model forms the theoretical context of  
Risk-Vulnerability hypothesis  
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K. H. Nuechterlein1 vulnerability/stress model of schizophrenic relapse: a longitudinal study;,
Acta Psychiatrica ScandinavicaVolume 89 Issue s382 ,58-64, 1994
Developmental and stress-related changes of neurotrophic 
factor gene expression in an animal model of schizophrenia
Maximizing outcome and preventing relapse : The necessary steps
Support & Monitoring
Family education and 
family therapy
Early detection 
and optimizing 
treatment 
Specific Suicide prevention 
program & strict 
monitoring for risk
Early Discharge with 
high quality care plan
Optimize 
Antipsychotic and 
Cognitive enhancers
Early 
Intervention, Hospit
alization and 
discharge
Work on acceptability 
an dattitude
What can a psychiatrist do?
Program based Intervention for psychosis: 
Advantages and Caution
• Much better than 
Treatment as usual
• Response, Recovery, 
outcome, Functioning & 
quality of life is better
• Relapse is less, 
• Disability and morbidity due 
to side effect is reduced
• Caution : Continuity of care 
is clinical and ethical issue
• Discharging patients out of 
program is likely to 
compromise quality of care.
• Caution : discharge  if  
remission has persisted for 
more than 5-7 years &
• subject has become over 
40 years of age
• family is nor dysfunctional
• Genetic loading is not very 
high
• Low risk for suicide
Research needs for Relapse Prevention
Most Important ones :
• Biological Markers for
– Course of psychosis
– Responders Vs Non-responders
– Endophenotypes of side effects of medications
– Antipsychotic response
• Determinants of ‘Insight’ and ‘awareness’
• Biological pathways for Cognitive dysfunction
• Markers fro stress response in psychosis
Summary:
Relapse Can be effectively minimized
• Relapse is common and main issue in outcome
• It is part of biological  nature of illness, mostly in first 5-7 
years
• Treatment barriers and risk factors for relapse needs to be 
identified and dealt with.
• Early Intervention, Education, Enhancing 
Compliance, Qualitative assessments, Safety of 
medication, Optimization of treatments are necessary
• Optimum Dose and adequate duration is a must.
• Program based Comprehensive and multidisciplinary 
treatment needs to be managed
